The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms Background: This multicenter study evaluated three candidate microRNAs (miRNAs) (miR-21, miR-155 and miR-101) as potential biomarkers in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
randomized, controlled trials, and these patients are usually treated with gemcitabine or 5-fluorouracil (eventually combined with radiotherapy), according to phase-III trials conducted in PDAC [14, 15] .
The identification of prognostic factors appears to be critical to tailor the optimal postoperative management of patients affected by invasive IPMNs. In our preliminary univariate analysis of patients resected for stage-II/III invasive IPMNs, lymph-node involvement (N1) was the main prognostic factor [16] . These patients were managed like patients diagnosed with PDAC, and adjuvant chemotherapy with gemcitabine for N1 patients resulted in a significantly improved survival. However, the molecular features characterizing the progression and chemosensitivity of these neoplasms are largely unknown. Previous studies revealed specific IPMN gene expression signatures [17, 18] , and the study of genetic and epigenetic mechanisms regulating the multistep processes involved in transcription or translation might unravel novel prognostic factors.
Recently, microRNAs (miRNAs) have emerged as a critical class of negative regulators of gene expression, through modulation of post-transcriptional activity of multiple target mRNAs. The role of miRNAs in the control of proliferation/ differentiation and apoptosis and their aberrant expression in many tumors indicated that they might function as tumorsuppressors and oncogenes. Aberrations of miRNAs are widespread across human cancers, and miRNA expression patterns classify tumors better than mRNA [19] , suggesting their use for diagnostic purposes. Furthermore, selected miRNAs may influence tumor behavior and response to chemotherapy [20] .
Our previous studies focusing on miR-21 showed that patients harboring high expression of this miRNA in their PDAC specimens had a significantly shorter survival after gemcitabine or 5-fluorouracil adjuvant therapies [21, 22] . The expression of miR-21 was significantly lower in the eight PDACs that clustered with the benign pancreas specimens in the study carried out by Bloomston and colleagues [23] , while profiling studies of miRNAs aberrantly expressed in PDAC show that miR-21 and miR-155 are among the top miRNAs with increased expression [23] [24] [25] . Elevated levels of miR-21 were already identified in noninvasive IPMNs [26] , as well as in the cyst fluid from 14 IPMNs, including 3 invasive IPMNs [27] . The expression of miR-155 was also significantly up-regulated in non-invasive IPMNs compared with matched non-neoplastic samples, and the expression of both miR-21 and miR-155 was more frequently detected in IPMNs with carcinoma in situ versus non-invasive IPMNs [26] . In contrast, a recent study comparing the levels of miR-101 in five non-invasive and five invasive IPMNs showed a significant lower expression in the invasive IPMNs, suggesting that the down-regulation of this miRNA underlines the increased expression of its target Enhancer of Zeste Homolog-2 (EZH2) in IPMN carcinogenesis [28] .
Currently, no data are available on the expression of miR-21, miR-155 and miR-101 in homogeneous larger cohorts of noninvasive and invasive IPMNs, nor on their correlation with outcome.
Therefore, the aim of the present study was to characterize the expression of these candidate miRNAs in a wide repository of well-characterized pancreatic specimens, including normal ductal tissues, non-invasive and invasive IPMNs, and to correlate these data with clinical outcomes.
patients and methods patients
Patients who underwent radical surgical resection ( pancreaticoduodenectomy, total-pancreatectomy and distal-pancreatectomy) at the Department of Surgery, Pisa University Hospital (Pisa, Italy) and the HPB Surgical Unit, Hammersmith Hospital (London, UK) between 2000 and 2010 were reviewed using electronic medical records. Among them, we collected information about clinicopathological characteristics and outcomes of 77 patients resected for invasive IPMNs and 17 for noninvasive IPMNs.
laser microdissection and RNA extraction RNA was successfully isolated from FFPE sections of 81 patients (65 invasive IPMNs and 16 non-invasive IPMNs), using the RecoverAll kit (Applied Biosystems, Foster City, CA). RNA quality was optimal, as demonstrated by the analysis with the Agilent-Bioanalyzer and by comparison with RNA obtained from 15 frozen samples (supplementary Figure S1 , available at Annals of Oncology online).
FFPE specimens were reviewed for diagnosis and tumor content, and IPMNs were classified for tumor grading as proposed by the WHO. The specimens were cut into 10-μm sections, fixed in 70% ethanol, stained for histological examination with hematoxylin/eosin and dehydratated by passing sequentially through 70%/96%/100% ethanol and xylene. A mean of 5000 neoplastic cells were dissected using the Leica-LMD6500 instrument (Leica, Wetzlar, Germany). Because of the long experience of our laboratory with this method, there was no difficulty in selecting areas with morphologically defined cancer cells [29] . The precision of the laser beam resulted in the capture of individual cells with high degree of accuracy ( Figure 1A-C) .
Laser microdissection was also used to obtain cells of epithelium ducts from five normal pancreatic tissues from the 'Organ Donor Program'. All specimens were obtained according to protocols approved by the local ethics committees.
expression analysis of miR-21, miR-155 and miR101
RNA (10-100 ng) was reverse-transcribed and the resulting cDNA was amplified using specific TaqMan® MicroRNA assays for miR-21, miR-155, miR-101 and RNU6 (Assay ID 000397, 002623, 002253 and 001093). PCR reactions were carried out in the ABI-Prism-7500HT instrument. Quantification of relative expression, normalized to RNU6, was carried out using the 2 −ΔCt method, as described [21] . expression differed significantly between grade-1/2 (n = 53) and grade-3 (n = 12) tumors (P = 0.03, Wilcoxon rank-sum test). No difference was detected in miR-21 levels according to other clinicopathological parameters (Table 2 ).
Significant differences between expression in normal tissues and non-invasive and invasive IPMNs were also detected for miR-155. Conversely, miR-101 expression values were similar in normal tissues and non-invasive IPMNs (median values of 8.6 and 9.8, respectively), whereas significantly lower values (median 2.71) were observed in invasive IPMNs.
correlation of miR-21, miR-155 and miR-101 with outcome
None of the patients with non-invasive IPMNs died as a consequence of the disease. Therefore, we focused on the association of miR-21, miR-155 and miR-101 expression with overall/disease-free survival (OS/DFS) in the invasive IPMNs cohort. Patients were categorized according to median expression values of each considered miRNA, according to their Gaussian distribution (supplementary Figure S2 , available at Annals of Oncology online).
Notably, a strong interaction of miR-21 expression status and clinical outcome was demonstrated (Table 3) Figure 2A and B). In contrast, no significant associations with outcomes were observed for either miR-155 or miR-101, and the analysis of clusters obtained taking into account the expression of the three miRNAs showed no significant correlation with either OS or DFS (supplementary Figure S3 , available at Annals of Oncology online).
Supplementary Table S1 , available at Annals of Oncology online summarizes the clinicopathological characteristics and their correlation with outcome. No significant association was observed between OS and DFS and the characteristics studied, except lymph-node and resection margin involvement ( Figure 2C-F) . 
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Univariate analysis demonstrated that lymph-node positive patients had significantly shorter OS and DFS (P < 0.001) compared with lymph-node negative patients. Similarly, patients with positive resection margins had median OS and DFS of 15.9 (95% CI = 1.8-30.0) and 4.6 (95% CI = 0.0-9.6) months, respectively, while patients with negative resection margins had median OS and DFS of 34.3 (95% CI = 12.4-56.3) and 17.9 (95% CI = 3.9-31.9) months, respectively.
To evaluate the risk of disease progression and death, we carried out two Cox regression analyses entering all the variables significantly associated with DFS and OS from the univariate model.
These multivariate analyses confirmed the independently prognostic significance of miR-21 expression and lymph-node involvement (Table 4) . High-miR-21 expression was significantly associated with an increased risk of death (HR = 3.3, 95% CI = 1.5-7.0, P = 0.02) and with an increased risk of progression (HR = 2.3, 95% CI = 1.2-4.8, P = 0.02).
The purpose of this analysis was to make an evaluation as to whether the expression of candidate miRNAs was associated with outcome. However, we also constructed separate Cox models for patients treated with adjuvant therapy versus patients without adjuvant therapy. Since the cases were not randomly assigned to receive treatment, we wanted to determine whether there were any significant differences in the covariate distribution between the patients with and without therapy (supplementary Table S2 , available at Annals of 
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Oncology online). Treated patients had significantly higher rates of T3-4 primary tumors and lymph-node involvement (P = 0.008 and 0.004, respectively) compared with untreated patients. Univariate analysis of these groups showed that only in the subgroup of adjuvant-treated patients, high-miR-21 status was associated with a significantly higher risk of death (supplementary Table S3 , available at Annals of Oncology online).
discussion
This study evaluated the impact of miR-21, miR-155 and miR-101 on outcomes of patients with invasive IPMNs, and to our knowledge, this study is the first to demonstrate the association of miR-21 expression with OS and DFS in patients who underwent radical resection.
Furthermore, we observed significant differences between miR-21 and miR-155 expression in normal versus non-invasive IPMNs versus invasive IPMNs, suggesting that increasing values of these miRNAs are correlated with the progression from benign lesions to invasive IPMNs. Conversely, the levels of miR-101 in normal specimens were similar to those detected in non-invasive IPMNs, but significantly higher with respect to invasive IPMNs, in agreement with a recent study comparing miR-101 levels in five non-invasive and five invasive IPMNs [28] .
Since WHO classification, IPMNs have been diagnosed with an increasing frequency [30] . They are now accepted as relatively common cystic pancreatic neoplasms, with a wide range of different pathological and clinical features, from minimal mucinous hyperplasia to adenoma to invasive carcinoma [31] . (A and B) , lymph-node status (C and D) and resection margins (E and F). OS was calculated from the date of surgery to the date of death, and DFS was defined as the time from the date of surgery to the date of first relapse or death. Statistical differences were analyzed using the log-rank test, as described in Methods. N0, negative lymph-node status; N1, positive lymph-node status; R0, negative resection margins; R1, positive resection margins.
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Patients affected by invasive IPMNs are usually treated with the same regimens used for PDACs, but their 5-year OS is ∼40%, which is far superior to OS after PDAC [13] . This suggests that although many genetic abnormalities described in conventional PDAC have also been observed in IPMNs, there are differences in the biology of these diseases. GNAS mutations, for instance, have been described in invasive IPMNs but not in PDAC [32, 33] . A better understanding of molecular and clinicopathological characteristics associated with outcome might improve the optimal management of patients resected for invasive IPMNs. Over the last few years, several pathological factors, such as tubular histology, tumor size, lymph-node status, tumor grade and vascular or perineural invasion, have been associated with dismal outcome of invasive IPMNs [11, 34, 35] . Other data suggested a benefit of chemoradiation, particularly in the presence of lymph-node metastases or positive margins [36] . In agreement with these data, we observed that patients with positive resection margins and lymph-node metastases had a significantly worse outcome.
Biological aspects underlying this differential invasive behavior, as well as prognosis and response to treatment of IPMNs, are still poorly understood. Therefore, in the present study, we systematically investigated the relationship of selected candidate miRNAs in terms of their clinical utility.
Following their recent discovery, miRNAs have been established as pivotal regulators of gene expression, potentially explaining the gap that frequently exists between tumor genotype and phenotype, and have provided a new dimension to cancer diagnosis and prognosis. Although the feasibility of an appropriate profiling of miRNAs from archival tissue is still a debate, technological advances have made it possible to reliably determine their expression using FFPE specimens, as demonstrated by our successful analysis of 81 samples. This approach is logistically more convenient than evaluating gene expression in frozen tissues, and has relevant implications in studies involving the pancreas, an organ with high endogenous nuclease activity, and a very small amount of tumor tissue available.
The miRNAs evaluated in our pancreatic specimens were carefully selected according to previous analyses in noninvasive and/or invasive IPMNs [26] [27] [28] . Moreover, studies in PDAC cells showed that these miRNAs were involved in (i) proliferation, invasion and chemoresistance to gemcitabine, through modulation of several direct and indirect targets, such as PTEN [21, 37] , whose expression was related to miR-21 also in our IPMNs (supplementary Figure S4 , available at Annals of Oncology online), (ii) repression by miR-155 of tumor protein 53-induced nuclear protein-1, which is a proapoptotic stressinduced p53 target [38] , and (iii) regulation by miR-101 of the key member of the Polycomb-group family EZH2 [28] , which can silence several tumor-suppressor genes, playing an outstanding role in cancer development, and is involved in chemoresistance to gemcitabine [39] .
A search carried out using TargetScan-v.6.1 identified a total of 308, 440 and 803 targets for miR-21, miR-155 and miR-101, respectively, with several common targets, including 17 genes in the KEGG-database signaling pathways of PDAC (supplementary Table S4 , Figure S5 and S6, available at Annals of Oncology online). However, it remains difficult to estimate the true false-positive rate of current target prediction algorithms, and future studies for the experimental validation of these targets are warranted.
Previous clinical studies demonstrated that miR-21 overexpression was predictive of shorter survival in PDAC patients treated in both the adjuvant and the palliative setting [21, 22, 40] , while the negative prognostic effects of miR-155 overexpression were observed in a cohort of PDACs, including patients with advanced disease and/or local R2-resection [41] . There is no report on correlation of miR-101 with PDAC outcome, but the expression of EZH2 has been associated with poor prognosis in PDAC patients [42] .
In our invasive IPMNs, miR-21 was the only miRNA significantly associated with OS and DFS. These results are consistent with a meta-analysis showing that elevated miR-21 expression predicted poor survival in patients affected by gastrointestinal cancers [43] .
Recent studies in miR-21-overexpressing mice established by Cre/Tet-off technologies confirmed the oncogenic role of miR-21, demonstrating its impact on tumor initiation, maintenance and invasion [44] . Taking into consideration the consistency and strength of these preclinical findings, as well as the almost omnipresent overexpression of miR-21 in human tumors, miR-21 has been referred to as an 'oncomir', which can be used for prognostic purposes.
However, the prognostic role of miR-21 might be treatmentrelated. Indeed, miR-21 expression was correlated with resistance to several anticancer agents [20, 45, 46] . In particular, suppression of miR-21 by anti-miR increased sensitivity and apoptosis induction by gemcitabine in PDAC [35, 47] . Furthermore, our previous study revealed that lowmiR-21 expression was associated with benefit from adjuvant therapy [22] , suggesting that high-miR-21 levels are predictive of worse treatment activity. In the present study, we also 
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observed that high-miR-21 status was associated with a significantly higher risk of death in the subgroup of adjuvanttreated patients. However, this observation was limited by the sample size of this subgroup and though OS and DFS represent the most objective outcomes in the retrospective setting to assess the response to treatment of pancreatic neoplasms and evaluate possible predictive markers, the planning of randomized studies with a control arm of patients treated with other regimens and the comparison of the survival stratified by miRNA expression would be the only way to establish the predictive role of these biomarkers [48] . A major strength of the present study is that it was carried out in a homogeneous setting of patients from a multicentric series, whose specimens have been carefully revised and lasermicrodissected. The results of multivariate analysis indicate the noteworthiness of the prognostic role of miR-21. Moreover, the positive association, detected using the median value of miR-21 expression as cut-off, demonstrated that our findings might be relevant to a large number of patients. Conversely, the main limitations included the relatively modest sample size and the retrospective design, implying that these results should be considered as hypothesis generators and should be further evaluated in larger and adequately designed retrospective/ prospective studies.
However, our results might also be important to hypothesize the differential biological significance of selected miRNAs in this specific clinical setting, with miR-101 (the 'good') expression potentially inhibiting mechanisms underlying tumor progression from non-invasive to invasive, whereas miR-155 (the 'ugly') and miR-21 (the 'bad') are significantly overexpressed in more aggressive tumors, with the latter also predicting worse outcome.
In conclusion, we report here for the first time that the expression of miR-21 is associated with survival of patients affected by invasive IPMNs. The differential expression of this miRNA, as well as of miR-155 and miR-101 in normal tissues, non-invasive IPMNs and invasive IPMNs, further supports the importance of these miRNAs in IPMN disease development. These data suggest also their possible use as biomarkers of potentially less aggressive IPMNs that, following sampling at endoscopic ultrasound, together with imaging and other biomarkers, could allow for conservative management, as recently described for specific miRNAs in pancreatic cyst fluid [49, 50] . Moreover, these miRNAs might be envisioned as potential novel therapeutic targets. Ultimately, the validation of the role of these miRNAs in prospective multicentric trials might offer new tools for the optimization of currently available treatments in selected IPMN patients. 
